Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's State Council Says CFDA Must Set Deadlines for Drug Approvals

publication date: Aug 20, 2015
By 2018, the CFDA must establish a specific limit for drug approval timelines, decreed China's State Council. Within that specified period of time, the CFDA must either approve or reject a drug. The ruling was one of several broad reform initiatives for drug and medical device approval procedures, released by the State Council earlier this week. The major emphasis is on safety and efficacy, especially for the generic products that constitute the majority of the country's drug supply. Now, it's up to the CFDA to establish specific policies that achieve the goals. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital